Specify a stock or a cryptocurrency in the search bar to get a summary
Mediwound Ltd
MDWDMediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel. Address: 42 Hayarkon Street, Yavne, Israel, 8122745
Analytics
WallStreet Target Price
29.75 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures MDWD
Dividend Analytics MDWD
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History MDWD
Stock Valuation MDWD
Financials MDWD
Results | 2019 | Dynamics |